



Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: Round 4 (2012)

Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: 4 (2012)

WHO Library Cataloguing-in-Publication Data :

Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 4 (2012).

1.Malaria - diagnosis. 2.Antimalarials - therapeutic use. 3.Malaria - drug therapy. 4.Diagnostic tests, Routine. 5.Reagent kits, Diagnostic - utilization. 6.Sensitivity and specificity. I.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. II.Centers for Disease Control (U.S.). III.Foundation for Innovative New Diagnostics.

ISBN 978 92 4 150472 0

(NLM classification: WC 750)

Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2012

All rights reserved.

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders. Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

WHO, including TDR, make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard.

Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR. WHO, including TDR, accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Layout: Bruno Duret

Printed in Italy

Contents

ACKNOWLEDGEMENTS	VIII
ABBREVIATIONS	X
1. SUMMARY PERFORMANCE OF MALARIA RDTs: WHO PRODUCT TESTING: ROUNDS 1–4	1
1.1. Introduction	1
1.2. The WHO Product Testing Programme	1
1.3. Results of the evaluation	2
1.4. Summary of outcomes	3
1.5. Use of these results	3
2. WHO MALARIA RDT PRODUCT TESTING: ROUND 4 EXECUTIVE SUMMARY	17
2.1. Introduction	17
2.2. The WHO Product Testing Programme	17
2.3. Results of the evaluation	18
2.4. Use of these results	18
3. BACKGROUND	19
4. OBJECTIVE	21
5. MATERIALS AND METHODS	21
5.1. Test selection	21
5.2. Outline of the Product Testing Protocol	21
5.3. Evaluation panels	24
5.4. RDT registration	25
5.5. Specimen panel registration	25
5.6. Test phases	25
5.7. Performing rapid tests	25
5.8. Interpretation of results	26
6. DATA MANAGEMENT	27
7. QUALITY ASSURANCE	27
8. ETHICAL CONSIDERATIONS	28
9. DATA ANALYSIS	28
9.1. Measures of parasite detection: panel detection score and positivity rates	28
9.2. False-positive results	28
9.2.1. Incorrect species identification	29
9.2.2. False-positives from <i>Plasmodium</i> -negative samples	29
9.3. Band intensity	29
9.4. Lot agreement	29
9.5. Invalid tests	29
9.6. Heat (thermal) stability	29
10. LABORATORY VERSUS FIELD-BASED MALARIA RDT EVALUATIONS	30

11. RESULTS	31
11.1. Summary	31
11.2. Phase 1 - <i>P. falciparum</i> culture panel	36
11.3. Phase 2 - Wild-type <i>P. falciparum</i> and <i>P. vivax</i> and <i>Plasmodium</i> spp. negative samples	37
11.3.1. <i>P. falciparum</i> detection	37
11.3.2. <i>P. vivax</i> detection	38
11.3.3. Combined detection of <i>P. falciparum</i> and <i>P. vivax</i>	38
11.3.4. <i>P. falciparum</i> and <i>P. vivax</i> positivity rate	39
11.3.5. Band intensity	40
11.3.6. False-positive rates	40
12. HEAT STABILITY	44
12.1. <i>P. falciparum</i> test lines	47
12.2. Pan-specific test lines	49
13. EASE-OF-USE DESCRIPTION	51
14. DISCUSSION OF KEY FINDINGS	55
14.1. Panel Detection Score (PDS) and its relationship to sensitivity	55
14.2. False-positive rate and specificity	56
14.3. Heat (thermal) stability	57
14.4. Ease-of-use description	57
14.5. Inter-lot variability	58
14.6. Target antigens and species	58
15. USING THESE RESULTS TO ENSURE QUALITY OF DIAGNOSIS IN THE FIELD	59
15.1. Beyond procurement	59
15.2. Lot testing	59
16. CONCLUSIONS	60
17. REFERENCES	60
ANNEXES	63
Annex 1: Characteristics of rapid malaria tests in Round 4	64
Annex 2: Malaria RDT guide to results interpretation	67
Annex 3: Phase 1 results	82
Annex 4: Phase 2 results	86
Annex 5a: Selection of an appropriate RDT	118
Annex 5b: Malaria RDT field assessment and RDT anomalies	119
Annex 6: Introducing RDT-based malaria diagnosis into national programmes	122

Reference to any company or product in this report, particularly in any of the figures or tables, does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) any list of companies or products is complete and/or error free; and/or that (2) any products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion in this report does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). Any lists of RDTs are not an exhaustive list of malaria RDTs. Such lists reflect those products which have been submitted for evaluation in Round 4 of the WHO Malaria RDT Product Testing Programme. The fact that certain products are not included in any list means that they have not or not yet been submitted for evaluation in the WHO Malaria RDT Product Testing Programme and does not indicate anything in respect of such products' performance. WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of or in connection with the procurement, distribution and use of any product whatsoever included in this report. This report may not be used by manufacturers and suppliers for commercial or promotional purposes.

FIGURES

- Figure S1: Malaria RDT performance in Phase 2 of Rounds 1–4 against wild-type (clinical) samples containing *P. falciparum* at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
- Figure S2: Malaria RDT performance in Phase 2 of Rounds 1–4 against wild-type (clinical) samples containing *P. vivax* at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
- Figure 1: Mode of action of antigen-detecting malaria RDTs
- Figure 2: Network of specimen collection, characterization and testing sites
- Figure 3: Malaria RDT Product Testing Overview
- Figure 4a: Origin of Phase 2 *P. falciparum* wild-type (clinical) samples
- Figure 4b: Origin of Phase 2 *P. vivax* wild-type (clinical) samples
- Figure 5: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 200 parasites/μl
- Figure 6: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 2000 parasites/μl
- Figure 7: Phase 1 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/μl) according to target antigen type (HRP2 or pLDH)
- Figure 8: Phase 2 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/μl) according to target antigen type (HRP2 or pLDH)
- Figure 9: Phase 2 *P. vivax* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/μl) according to target antigen type (aldolase, pLDH)
- Figure 10: Phase 2 *P. falciparum* panel detection score and positivity rate at 200 parasites/μl
- Figure 11: Phase 2 *P. vivax* panel detection score and positivity rate at 200 parasites/μl
- Figure 12: Phase 2 *P. falciparum* (*P. falciparum* test line) false-positive rate against clean-negative samples
- Figure 13: Phase 2 *Plasmodium* spp. (pan or *P. vivax*/Pvom test line) false-positive rate against clean-negative samples
- Figure 14: Phase 2 *P. falciparum* false-positive rate versus *P. falciparum* panel detection score at low (200) parasite density (parasites/μl)
- Figure 15: Phase 2 *P. vivax* false-positive rate versus *P. vivax* panel detection score at low (200) parasite density (parasites/μl)
- Figure 16: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 17: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 18: Heat stability of *P. falciparum*-specific test line in combination tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 19: Heat stability of *P. falciparum* specific test line in combination tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 20: Heat stability of pan-line of pan-specific tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 21: Heat stability of pan-line of pan-specific tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 22: Heat stability of pan-line of combination tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 23: Heat stability of pan-line of combination tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure A5.1: How to select of an appropriate RDT
- Figure A5.2: Malaria RDT anomalies encountered in production lots
- Figure A6.1: Example of malaria RDT implementation steps and timeline
- Figure A6.2: Components of the budget for a malaria diagnosis programme

TABLES

Table S1:	Malaria RDT Phase 2 performance in Rounds 1–4 against wild-type (clinical) samples containing <i>P. falciparum</i> and <i>P. vivax</i> at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
Table S2:	Malaria RDT Rounds 1–4 heat stability results on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite density (parasites/μl). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C
Table S3:	Product resubmissions: WHO Malaria RDT Product Testing (Rounds 1–4)
Table 1:	Manufacturers and products accepted into Round 4 of WHO Malaria RDT Product Testing Programme
Table 2:	Characteristics of <i>Plasmodium</i> spp. negative specimens
Table 3:	Summary Phase 1 performance of 48 malaria RDTs against 20 cultured <i>P. falciparum</i> lines at low (200) and high (2000) parasite densities (parasites/μl)
Table 4:	Summary Phase 2 performance of 46 malaria RDTs against wild-type (clinical) <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/μl) and <i>Plasmodium</i> spp. negative samples
Table 5:	Heat stability testing results for 46 malaria RDTs on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite densities (parasites/μl). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C
Table 6:	Ease-of-use description of 48 malaria RDTs
Table A3.1:	Lot variability in positive results against <i>P. falciparum</i> culture samples at low (200) and high (2000 or 5000) parasite densities (parasites/μl)
Table A3.2:	Distribution of test band intensity scores (0–4) against Phase 1 <i>P. falciparum</i> cultured parasites at low (200) and high (2000) parasite densities (parasites/μl)
Table A4.1:	Lot variability in positive results against Phase 2 wild-type <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/μl)
Table A4.2:	Distribution of test band intensity (0–4) scores against Phase 2 wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite densities (parasites/μl)
Table A4.3:	Distribution of Pan/Pv test band intensity (0–4) scores for Phase 2 wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/μl)
Table A4.4:	Panel detection score of Phase 2 wild-type <i>P. falciparum</i> in low (200) and high (2000) parasite densities (parasites/μl) by continent
Table A4.5:	Phase 2 <i>P. falciparum</i> test line false-positive rates for wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/μl)
Table A4.6:	Phase 2 Pan (or <i>P. vivax</i>) test line false-positive rate for non-Pf infection on wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite densities (parasites/μl)
Table A4.7:	Phase 2 false-positive rate for <i>P. falciparum</i> test line results on all malaria-negative samples

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28297

